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ABSTRACT
Objectives: Polycystic ovary syndrome (PCOS) is a complex reproductive endocrinopathy among reproductive-
aged women and related with body mass and insulin resistance. Adipocytokines produced by adipose tissue seems to 
take part in the hormonal and metabolic alterations that arise in PCOS. Fat mass and obesity associated (FTO) gene is 
linked with body mass index (BMI) and diabetes. 
Aims — To investigate the association between fat mass related adipocytokines and single nucleotide 
polymorphisms (SNPs) (rs9939609 T/A) in the FTO gene in women with PCOS.
Material and methods: FTO+rs9939609 gene polymorphism and serum spexin, adiponectin and leptin levels were 
deter-mined in 91 PCOS women and 86 healthy controls. Study participants were subdivided according to BMI and 
comparisons were made within each group. 
Results: Serum spexin levels were not differed between study groups. Serum levels of adiponectin were found to be 
de-creased in PCOS women with BMI lower than 25 kg/m2 (10.1 ± 5.6 vs 14.1 ± 9.1, p = 0.015). Serum leptin levels were 
elevated in obese PCOS women compared to healthy control group (2197.9 ± 596.3 pg/mL vs 1535.9 ± 812.1 pg/mL, p = 
0.001). The prevalence of A risk allele of SNP rs9939609 was more frequent in PCOS patients than in the control group. 
PCOS risk was found to increase 3 times more in AA genotype when compared with TT genotype (OR = 3.04 95% CI: 1.243–
7.309; p = 0.013).
Conclusions: Serum adiponectin and leptin levels may serve as independent markers for PCOS diagnosis. Moreover, 
the FTO+rs9939609 gene polymorphism increase susceptibility to PCOS development independent from serum adipocytokine 
levels. 
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INTRODUCTION
Polycystic ovarian syndrome (PCOS) is a common 
and serious cause of infertility which affects nearly five 
to ten percent of women of childbearing age across the 
World [1]. Although the clinical reflection of the disease 
can be variable, diagnostic characteristics commonly 
involve clinical complaints including menstrual irregularities 
that range from amenorrhea to menorrhagia, increased 
androgen secretion and/or polycystic ovaries [2]. In this 
context, the phenotypic expression varies in PCOS patients 
depending on whether the patient is lean, obese or having 
insulin resistance (IR) and increased adipokine expression 
regardless of the patient’s body mass index (BMI) [3, 4]. 
There has been growing evidence that shows genetic 
aberrations also contribute to disease development by 
inducing immune and autoimmune responses [5, 6]. 
Recently, more than one hundred candidate genes have 
been identified regarding the possible relationships 
between PCOS and single nucleotide polymorphism (SNP), 
for instance body mass and genetic variants of obesity 
associated (FTO) gene [7, 8]. The human FTO is a very large 
gene that is positioned on chromosome 16q12.2 with 
an extensive expression range in many human tissues [9]. 
Recent studies demonstrated that the FTO gene expression 
is strongly related with obesity by its impact on feeding 
behavior and energy expenditure [10, 11]. However, data 
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regarding these associations and the pathophysiologic 
mechanisms underlying them needs further clarification. 
Central obesity is the cornerstone of a variety of 
metabolic disorders, such as IR and coronary atherosclerosis 
and is an important element of metabolic syndrome. It has 
been suggested that dysregulation of adipocytokines is 
partly responsible for this obesity associated metabolic 
disorders [11]. Being a disease related with IR and central 
obesity, the role of adipose tissue adipocytokines has been 
implicated to play important roles in the pathogenesis of 
PCOS in the recent years.
Adipocytokines are proteins that have hormone like 
functions and secreted by the adipocytes in the adipose 
tissue [12]. The most significant physiological functions of 
adipose tissue are the regulation of physiological processes 
such as immune responses, reproduction, and energy 
hemostasis [4]. Adipocytokines that are expressed by the 
adipocytes consists of adiponectin, leptin, spexin, apelin, 
omentin, resistin, progranulin and chemerin. Adiponectin 
and leptin are two important adipocytokines and both 
have an effect on obesity, cardiovascular disease, type 
2 diabetes mellitus and IR [13]. Adiponectin is an anti-
inflammatory cytokine that regulates glucose and fatty 
acid metabolism, thus inversely related with the adipocyte 
mass and visceral adiposity. Leptin is a peptide hormone 
with neuroendocrine function that regulates in the energy 
homeostasis with having a key function in the peripheral 
regulation of food intake and energy expenditure and 
thereby IR [14, 15]. Spexin is a neuropeptide identified by 
a hidden Markov model based on a computational method 
in order to detect novel biologically active peptides [16, 
17]. Although, there is growing evidence on the existence 
of spexin gene expression in the adrenal cortex, kidney, 
liver, visceral fat and pancreas, very little is known about 
the association between ovaries and spexin expression. 
As far as we know, no study in the literature has in-
vestigated the circulating spexin levels in PCOS women. 
Furthermore, the potential relationships of spexin and two 
other adipocytokines with body mass and associated meta-
bolic disorders have not been well-examined. This study is, 
therefore, aimed to investigate the relationships between 
spexin, adiponectin, leptin and obesity associated meta-
bolic disorders and FTO rs9939609 gene polymorphism in 
PCOS women. 
MATERIAL AND METHODS
Study design and subjects
This cross-sectional study was conducted from August 
2017 to September 2018 at the Canakkale University Hospital 
in Canakkale, Turkey. All participants attending to the 
Department of Obstetrics and Gynecology of COMU hospital 
with a diagnosis of PCOS were invited to participate in the 
study. The exclusion criteria included previous systemic, 
metabolic or endocrine disorders. Moreover, patients 
with thyroid disorders and arterial hypertension [systolic 
blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood 
pressure (DBP) ≥ 90 mmHg] prior to use of oral contraceptive 
agents; severe lipid profile abnormalities with/or without 
antihyperlipidemic drugs; or prescription of gonadotropin-
releasing hormone agonists or antagonists, glucocorticoids, 
or antidiabetic drugs within the previous three months were 
also considered as exclusion criteria for the present study. 
All study participants gave written informed consent, 
and the study was approved by the Canakkale University 
Human Research Ethics Committee (approval number: 
2017-15). PCOS diagnosis was done based on the revised 
criteria of Rotterdam 2003. According to this consensus 
report, the diagnosis of PCOS can be considered after 
suitable clinical, laboratory and ultrasound criteria are 
fulfilled. The presence of at least two of the following three 
features are thought to be suitable for the exact diagnosis: 
oligomenorrhea or amenorrhea longer than 6 months, 
clinical and/or biochemical indicators of high levels of 
androgens, and finally, polycystic ovaries (≥12 follicles) 
and/or increased ovarian volume (> 10 cm3) which is 
identified by ultrasonographic examination. 
Healthy controls were recruited from the Gynecology 
and Obstetrics clinic of Canakkale University Hospital. 
The control group consisted of 86 healthy, age-matched, 
normally ovulating women without any systemic or 
hormonal disorders. None of the controls were hirsute, all 
had regular menstrual cycle, and all had normal ovaries on 
ultrasonographic examination. Moreover, the volunteers in 
the control group had no clinical evidence of acne, hirsutism, 
male pattern alopecia, or any other endocrine disorder.
For each patient, height and weight were recorded in 
indoor clothing with no shoes. BMI was calculated as weight 
in kilograms divided by height squared (m2).
Biochemical analyses
Between days 3–5 of a spontaneous menstrual cycle, 
a 6-mL fasting blood sample for hormonal and biochemi-
cal analysis and a 4-mL fasting blood sample for genotyp-
ing examination were drawn from the antecubital vein of 
each subject. The samples for biochemical analysis were 
subjected to centrifugation at a speed of 4,000 rounds per 
minute for 10 min at 4°C to obtain serum and stored for 
analysis at –80°C. Routine biochemical analysis and hor-
mone profiles including fasting glucose, fasting insulin, prol-
actin, estradiol, luteinizing hormone (LH), follicle stimulating 
hormone (FSH), thyroid stimulating hormone (TSH), and 
total testosterone were measured for all participants. Bio-
chemical tests were analyzed spectrophotometrically, using 
the Roche Diagnostic kits on the Cobas c501 auto-analyzer 
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(Roche Diagnostics, Indianapolis, USA). Hormone tests were 
measured with the original Roche Diagnostic kits on the 
Cobas e601 using the electrochemiluminescence immu-
noassay method (Roche Diagnostics, Indianapolis, USA). 
IR was assessed by the Homeostasis Model of Assessment 
— Insulin Resistance (HOMA-IR) index [18]. 
Spexin, adiponectin and leptin measurement
Serum Spexin (EH4349, Fine Test, Wuhan, China), adi-
ponectin (EH2593, Fine Test, Wuhan, China) and leptin 
(EH0216, Fine Test, Wuhan, China) concentrations were 
measured with an ELISA kit. Leptin and Spexin results were 
expressed as nanograms in per liter (pg/L) of serum. Adi-
ponectin results were expressed as picograms in per liter 
(ng/L) of serum. The intra-assay and inter-assay coefficients 
of variations were <8% and <10% for all parameters, re-
spectively.
Genotyping
PCOS patients and healthy controls were genotyped at 
the Department of Medical Biology of Canakkale Onsekiz 
Mart University. The venous blood samples of both patients 
and control groups were collected in vacuum collection 
tubes containing EDTA. The Genomic DNA extracted from 
peripheral blood sample of all study participants and the 
assessment was done according to manufacturers’ recom-
mendations (Thermo Fisher Scientific, USA). DNA purity 
and concentration were calculated at 260/280 nm by UV 
spectrometer. 
Single nucleotide polymorphism (SNP) rs9939609 (A/T) of 
FTO was genotyped directly by melting curve analyses. Briefly, 
real time polymerase chain reaction (PCR) was performed for 
each sample in a total volume of 10 µL PCR reaction mixture 
that consisted of 50 ng of genomic DNA, 5 μL of SYBR® Green 
Realtime PCR Master Mix (Analytic-Jena, Germany), and 
0.4 μL of each primer (10 pmol/μL) filled with PCR-grade 
water. The PCR cycling protocol included initial activation 
at 95°C for 3 minutes, 40 cycles of denaturation at 95°C for 
5 seconds, annealing at 60°C for 20 seconds, and extension 
at 72°C for 15 seconds. Melting curve analyses following PCR 
were performed to determine mutant, heterozygous, and 
wild-type genotypes.
Statistical analyses
Statistical Package for Social Sciences (SPSS) for 
Windows 19.0 (SPSS for Windows, SPSS, Chicago) was used 
for data analysis. Biochemical and hormonal parameter 
data are presented as mean ± SD for normally distributed 
variables. The normality of numeric variables was checked 
by Kolmogorov-Smirnov test. Independent sample t test was 
used to compare the numeric variables that were normally 
distributed and Mann-Whitney U test was used to compare 
the variables that non-normally distributed. Spearman’s 
correlation coefficient analyses were performed between 
spexin, adiponectin and leptin with other biochemical and 
hormonal parameters, and p-value < 0.05 was considered 
statistically significant. Gene-counting method was used 
to calculate allele and genotype frequencies. Genotype 
associations and relative risk assessments were done via 
odds ratio (OR) by using the Armitage trend test. 
RESULTS
The demographic and biochemical characteristics of 
the study participants are summarized in Table 1. Although, 
mean age of PCOS patients and controls were similar 
(26.5 ± 6.2 vs 28.8 ± 7.2, p = 0.050), PCOS women had 
a greater BMI (26.0 ± 5.3 vs 24.1 ± 4.4, p = 0.008) than the 
healthy women. A statistically significant increase was 
observed in body weight, insulin levels and HOMA-IR status 
in PCOS patients compared to controls. Moreover, PCOS 
patients had a significant increase in LH, total testosterone, 
and TSH levels (Tab. 1). 
Serum spexin levels were similar in PCOS women. Al-
though serum levels of adiponectin were decreased in 
women with PCOS either in obese (10.2 ± 6.7 ng/mL vs 
13.5 ± 8.2 ng/mL, p = 0.303) or normal weight PCOS women 
(10.1 ± 5.6 ng/mL vs 14.1 ± 9.1 ng/mL, p = 0.015), a sta-
tistical significance was observed only in normal weight 
PCOS subjects. Serum leptin levels were found to be in-
creased in obese PCOS patients compared to controls 
(2197.9.3 ± 596.3 pg/mL vs 1535.9 ± 812.1 pg/mL, p = 0.001) 
(Tab. 1).
We explored potential correlations among serum 
spexin, adiponectin and leptin levels with other demo-
graphic, hormonal and clinical characteristics in PCOS 
patients. No significant correlation was observed between 
these parameters in PCOS patients except for spexin and 
adiponectin in BMI < 25 kg/m2 PCOS group (r = 0.356, 
p = 0.021) (Tab. 2).
The correlation of FTO+ rs9939609 polymorphism 
with PCOS was examined by comparing PCOS patients 
with healthy volunteers. The distribution of the geno-
types in the PCOS group were as follows: out of 91 cas-
es, 29 were determined to have the wild (TT) genotype, 
41 the heterozygous genotype (AT), and 21 the mutant 
genotype (AA). The wild allele frequency (T allele) 
for FTO+rs9939609 polymorphism was calculated as 
0.53 ± 0.039 among PCOS patients, and the PCOS population 
was found to deviate from the Hardy-Weinberg equilibrium 
(HWE) (χ²: 0.047; p-value: 0.224). The wild allele frequency 
(T allele) for FTO+ rs9939609 polymorphism was calculated 
as 0.66 ± 0.037, and none of the variants were found to 
deviate from the HWE in the control group (χ²: 0.046; 
p-value: 0.829) (Tab. 3).
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Table 1. Demographic characteristics and laboratory values of study participants












(n = 30) p
Age 
[years] 26.5 ± 6.2 28.8 ± 7.2 0.050 25.7 ± 5.5 27.1 ± 6.3 0.424 27.1 ± 6.7 31.8 ± 7.7 0.007
Weight 
[kg] 70.3 ± 14.6 64.7 ± 11.4 0.005 58.9 ± 7.2 58.6 ± 6.5 0.859 80.1 ± 11.9 75.9 ± 10.1 0.116
BMI 
[kg/m2] 26.0 ± 5.3 24.1 ± 4.4 0.008 21.7 ± 2.4 21.5 ± 2.1 0.528 29.7 ± 4.0 28.9 ± 3.4 0.446
Glucose 
[mg/dL] 93.8 ± 13.8 93.5 ± 17.4 0.792 92.6 ± 12.6 90.9 ± 13.1 0.778 94.8 ± 14.9 98.4 ± 22.8 0.812
Insulin 
[μIU/mL] 12.8 ± 9.0 8.2 ± 5.5 0.0001 9.9 ± 7.1 7.8 ± 5.4 0.057 15.2 ± 9.9 9.1 ± 5.7 0.001
HOMA-IR 
[%] 2.9 ± 2.1 1.9 ± 1.4 0.0001 2.3 ± 1.8 1.8 ± 1.3 0.051 3.4 ± 2.2 2.3 ± 1.5 0.008
TSH 
[μIU/mL] 2.4 ± 1.1 2.2 ± 1.2 0.043 2.4 ± 1.1 2.2 ± 1.3 0.101 2.5 ± 1.1 2.3 ± 0.9 0.379
FSH 
[mIU/mL] 5.9 ± 1.9 5.3 ± 2.2 0.056 6.1 ± 1.9 5.1 ± 2.0 0.009 5.7 ± 1.9 5.8 ± 2.4 0.854
LH 
[mIU/mL] 7.8 ± 2.9 6.4 ± 3.9 0.001 7.9 ± 2.7 6.1 ± 3.8 0.003 7.8 ± 3.1 6.9 ± 4.4 0.189
TT 
[pg/mL] 0.4 ± 0.2 0.3 ± 0.1 0.0001 0.3 ± 0.2 0.3 ± 0.1 0.082 0.4 ± 0.2 0.3 ± 0.2 0.002
Spexin 
[ng/mL] 10.5 ± 9.2 12.6 ± 9.8 0.085 8.9 ± 6.4 12.4 ± 10.5 0.452 11.9 ± 10.9 12.9 ± 8.3 0.303
Adiponectin 
[ng/mL] 10.2 ± 6.2 13.9 ± 8.8 0.002 10.1 ± 5.6 14.1 ± 9.1 0.015* 10.2 ± 6.7 13.5 ± 8.2 0.056
Leptin 
[pg/mL] 1874.2 ± 902.3 1670.8 ± 786.1 0.112 1646.5 ± 602.9 1743.0 ± 769.5 0.112 2197.9.3 ± 596.3 1535.9 ± 812.1 0.001
BMI — body-mass index; HOMA-IR — homeostatic model assessment of insulin resistance; TSH — thyroid stimulating hormone; FSH — follicle-stimulating hormone; 
LH — luteinizing hormone; TT — total testosterone
Table 2.  Correlation between serum spexin, adiponektin and leptin levels with biochemical and hormonal parameters.
PCOS patients (BMI < 25 kg/m2) Controls (BMI ≥ 25 kg/m2)
Spexin Adiponectin Leptin Spexin Adiponectin Leptin
r p r p r p r p r p r p
BMI [kg/m2] –0.110 0.489 –0.003 0.987 0.172 0.277 0.045 0.759 0.189 0.192 0.396 0.005
HOMA-IR [%] 0.053 0.740 –0.097 0.541 0.028 0.861 0.095 0.515 0.031 0.835 0.161 0.269
TSH [μIU/mL] –0.052 0.743 0.062 0.696 –0.097 0.543 –0.003 0.986 –0.055 0.709 –0.022 0.881
FSH [mIU/mL] 0.051 0.750 –0.110 0.486 0.185 0.241 0.139 0.342 0.069 0.639 –0.080 0.586
LH [mIU/mL] –0.009 0.953 –0.218 0.166 0.087 0.585 –0.009 0.953 0.022 0.883 –0.023 0.878
TT [pg/mL] 0.038 0.812 –0.105 0.514 –0.072 0.655 –0.105 0.489 –0.340 0.051 0.083 0.584
Estradiol 0.023 0.886 0.174 0.271 0.098 0.536 0.119 0.416 0.148 0.310 –0.241 0.096
Spexin [ng/mL] – – 0.356 0.021 0.529 0.526 – – 0.143 0.326 0.210 0.148
Adiponectin [ng/mL] – – – – 0.194 0.217 – – – – –0.067 0.648
Leptin [pg/mL]
BMI — body mass index; HOMA-IR — homeostasis model assessment of insulin resistance; TSH — thyroid stimulating hormone;FSH — follicle-stimulating hormone; 
LH — luteinizing hormone; TT — total testosterone
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Genotype distribution in the control group was as fol-
lows: out of 86 cases, 38 had the wild (TT) genotype, 38 had 
the heterozygous genotype (AT), and 10 had the mutant 
genotype (AA). The frequency of the A-allele carriers on 
rs9939609 was significantly increased in PCOS cases com-
pared with healthy controls (46,6% vs 33,5% respectively, 
p = 0.01). The present data indicates that the conversion of 
a T allele to A in PCOS cases (allele frequency differences) 
increased PCOS risk 1.74 times when compared the general 
healthy women population [OR = 1.74; CI = (1.131–2.675); 
χ² = 6.40, p = 0.0114] (Tab. 3). When homozygous genotypes 
compared each other’s PCOS patients with AA genotype 
increase the risk approximately three times more than wild 
type genotype [TT vs AA genotype, OR = 3.014, CI = (1.24–
7.31); χ² = 6.18, p = 0.013]. Furthermore, rs9939609 was 
found significantly associated with PCOS under a recessive 
model [OR = 2.5; CI = (1.11–5.62); p = 0.027]. 
No significant difference was observed in PCOS women 
in respect to serum spexin, adiponectin and leptin levels in 
carriers of the genotypes of FTO+ rs9939609 polymorphism 
(p > 0.05 for all). In the healthy controls, serum spexin, adi-
ponectin and leptin levels in carriers of genotypes TT, AT, 
and AA of FTO rs9939609 polymorphism were also not 
significantly different (Tab. 4).
DISCUSSION
PCOS is associated with gradual weight gain, obesity 
and development of metabolic syndrome with dyslipidemia 
and IR. In this context, adipocytokine dysregulation 
and genetic aberrations are common features of PCOS 
and these alterations are usually secondary to obesity, 
hyperandrogenism, and/or hyperinsulinemia. Our findings 
in the present study strongly support these observations 
indicating that serum adiponectin and leptin levels 
are affected in PCOS patients depending on the BMI 
status. Serum spexin levels did not differ between study 
groups. No significant correlation observed between serum 
spexin levels and other two adipocytokines except for 
adiponectin in PCOS patients with BMI < 25 kg/m2. 
Our finding that spexin concentration did not vary sig-
nificantly between obese and lean PCOS patients vs healthy 
controls is of great value because there is no study in litera-
ture depicting the role of spexin in PCOS patients. Moreo-
ver, we could not identify any relation between circulating 
spexin and other metabolic or hormonal characteristics, 
including body composition or IR. Spexin is a novel peptide 
hormone that was first identified by Mirabeau et al. [16], by 
using an approach based on hidden Markov model. It has 
been shown to be involved in weight regulation with poten-
Table 3. Distributions of genotype and carriage rate of FTO promoter region polymorphisms in patients with PCOS and healthy controls.
SNP
Tests for deviation from 
Hardy-Weinberg equilibrium Tests for association (95% CI)










nTT =  38 (37.56) 
nAT =  38 (37.89) 
nAA =  10 (9.56) 
f_a1 =  0.66 ± 0.037 
F =  0.0234 
p = 0.829 (Pearson)
p = 0.829 (Llr) 
p = 0.81   (Exact)
nTT =  29 (26.1) 
nAT = 41 (45.8) 
nAA = 21 (20.1) 
f_a1 = 0.53 ± 0.039 
F = 0.1267 
p = 0.224 (Pearson) 
p = 0.224 (Llr) 
p = 0.216 (Exact)
Risk allele T
[T]<–>[A] [TT]<–>[AT] [TT]<–>[AA] [TT]<–>[AT+AA] Common OR
Odds_ratio = 1.74  
C.I. = [1.131–2.675] 
chi2 = 6.4  
p = 0.0114 (P)
Odds_ratio = 1.417  
C.I. = [0.733–2.736]  
chi2 = 1.08  
p = 0.299
Odds_
ratio = 3.014  
C.I. = [1.243–7.309]  
chi2 = 6.18  
p = 0.0129
Odds_
ratio = 1.756  
C.I. = [0.95–3.244]  
chi2 = 3.26  
p = 0.071
Odds_
ratio = 1.705 
chi2 = 5.84  
p = 0.0157
OR — odds ratio; CI — confidence interval
Table 4. Serum Spexin, Adiponectin, Leptin and body mass index levels of polycystic ovarian syndrome patients and controls with different genotypes of 
FTO gene polymorphism
Control Group (n = 86) PCOS patients  (n = 91)
AA (n = 10) AT (n = 38) TT (n = 38) Total AA (n = 21) AT (n = 41) TT (n = 29) Total p
Spexin [ng/mL] 11.27 ± 8.01 10.62 ± 6.49 14.794 ± 12.35 12.61 ± 9.76 11.92 ± 8.29 9.65 ± 8.36 10.89 ± 10.91 10.54 ± 9.20 0.143
Adionectin [ng/mL] 12.25 ± 7.13 12.83 ± 8.33 15.09 ± 9.55 10.15 ± 6.15 11.122 ± 7.33 9.85 ± 5.74 10.22 ± 6.18 13.88 ± 8.76 0.471
Leptin [pg/mL] 1591.1 ± 639.5 1698.0 ± 877.8 1697.9 ± 724.8 1670.8 ± 786.1 1913.6 ± 1062.3 1820.0 ± 897.3 1867.3 ± 823.5 1874.2 ± 902.3 0.21
BMI [kg/m2] 23.99 ± 5.18 24.69 ± 4.10 23.61 ± 4.63 24.09 ± 4.43 26.55 ± 6.69 25.71 ± 4.95 25.84 ± 4.44 26.01  ± 5.25 0.80
HOMA–IR 1.71 ± 1.84 1.84 ± 1.11 2.11 ± 1.50 1.93 ± 1.38 3.25 ± 2.63 2.84 ± 2.23 2.57 ± 1.17 2.88 ± 2.06 0.62
BMI — body mass index; PCOS — polycystic ovarian syndrome
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tial for obesity treatment and has been demonstrated to be 
expressed in a variety of body organs and tissues [17, 19, 20]. 
The finding of spexin levels that were not affected from BMI 
levels of study participants is not an expected result accord-
ing to the literature. It is expected that the spexin level must 
be higher in obese cases because it is produced in fatty tis-
sue. So, it can be proposed that similar spexin levels in PCOS 
cases irrespective from BMI status have a different etiologic 
mechanism. In a recent study by Chen et al. [21], it has been 
demonstrated that serum spexin levels are decreased in 
obese subjects and was negatively correlated with insulin 
resistance. Similarly, Al-Daghri and colleagues [17] demon-
strated that low serum levels of spexin are slightly related 
with components of metabolic syndrome. 
In this study, we also demonstrated that PCOS women 
have low levels of adiponectin and this finding is dependent 
on BMI. Therefore, the outcomes of the present study support 
the current knowledge indicating that a link exists between 
PCOS and decreased serum adiponectin levels. Apart from be-
ing an exclusive product of adipocyte cells, adiponectin plays 
a significant role in different physiological and pathological 
processes including inflammation, metabolic syndrome and 
atherosclerosis [22, 23]. Thus, obesity is an essential character-
istic of PCOS, which can decrease the quantity of adiponectin 
by modifications in the expression of adiponectin receptors 
and diminishes the adiponectin sensitivity. Therefore, de-
creased serum levels of adiponectin among the overweight 
patients with PCOS were mainly ascribed to the coexistence 
or interaction between PCOS and obesity [23]. Contrary to 
these findings Panidis et al. [24], demonstrated that adiponec-
tin levels were only lower in overweight/obese patients with 
PCOS compared to healthy non-obese PCOS patients. There-
fore, authors suggested that adiponectin might not have 
a significant role in PCOS pathogenesis. 
We found significantly increased serum leptin levels 
in PCOS women compared to healthy controls. There are 
different studies in literature reaching varied conclusions 
where both high concentrations and unchanged levels of 
leptin in PCOS patients have been determined [23, 25–27]. 
Daghestani et al. [27], reported no significant difference be-
tween PCOS and controls in terms of leptin levels. But similar 
to our findings, Mitkov et al [28], Pekhlivanov et al. [29], and 
Yang et al. [30], reported increased leptin levels in PCOS pa-
tients. Therefore, it can be suggested that with having a dual 
effect on reproduction, elevated serum leptin levels may 
have a pathophysiological role in PCOS development [27].
As mentioned above, the association between 
PCOS and different kind of adipocytokines has been 
well documented in literature, but the relation between 
FTO+ rs9939609 variant and these variables has not been 
well studied. In this context, this study also explored wheth-
er FTO gene polymorphism influences PCOS development 
or if there is a possible association between circulating adi-
pocytokines and FTO rs9939609 variant. We found that the 
variant allele of FTO rs9939609 was related with PCOS devel-
opment. Our finding is in line with the research findings of 
Li et al. [31], in which the authors designed a two-phase trial 
consisting 3599 PCOS women and 3082 healthy controls. 
As a result, they have demonstrated that FTO rs9939609 var-
iant is associated with Chinese PCOS women irrespective 
from the existence of obesity. A recent meta-analysis by Liu 
et al. [32], also confirmed these findings and demonstrated 
that rs9939609 A/T polymorphism of FTO gene is related 
with increased risk of PCOS development, and that A al-
lele is a risk factor for PCOS susceptibility simultaneously. 
Although, the function, the involved biological pathways 
and the mechanism by which the FTO rs9939609 variant 
affects body size and predicts the risk of PCOS is still in-
definite, this association is more likely to be explained by 
increased adiposity. Unfortunately, we are unable to dem-
onstrate the association between FTO rs9939609 variant 
with BMI and circulating adipocytokines, which could be 
due to inadequate power of the study.
It is crucial to recognize some limitations associated with 
the present study that could potentially offer a platform for 
future studies. First, the serum adipocytokine levels may 
not reflect all events associated to adipocytokines. It would 
have been noteworthy to measure inflammation markers 
simultaneously given that PCOS and obesity are associated 
to long-standing low-grade inflammation. Second, due to 
relatively small size of study population large-scale studies 
are required to confirm the association between FTO SNPs 
and PCOS susceptibility.
CONCLUSIONS
In conclusion, we demonstrated lower levels of adi-
ponectin, increased levels of leptin and unaltered spexin 
levels in PCOS patients. Moreover, we reported that single 
nucleotide polymorphisms (SNPs) in the FTO gene modify 
PCOS risk and does not appear to be influenced by IR status 
or obesity.
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